Hottest Stock Pick for 2021
This could be the most underrated stock available. Watch it closely.
Click here to learn more

NCYT Insider Trading (Novacyt)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £7,722
Insider Selling (Last 12 Months): GBX 0

Novacyt Insider Trading History Chart

This chart shows the insider buying and selling history at Novacyt by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Novacyt Share Price & Price History

Current Price: GBX 248.20
Price Change: Price Decrease of -3.1 (-1.23%)
As of 10/27/2021 05:35 PM ET

This chart shows the closing price history over time for NCYT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Fake meat? This company is cornering the plant-based market
This could become one of the greatest growth stories of our lifetimes

This tiny plant-based firm has explosive growth
Get the FREE investor deck

Novacyt Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/10/2020Edwin SnapeInsiderBuy1,080GBX 715£7,722
6/3/2020Andrew HeathInsiderBuy3,161GBX 305£9,641.05
5/15/2020James WakefieldInsiderBuy20,000GBX 305£61,000
See Full Table
Insider Selling at Novacyt?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Novacyt and related companies.

SEC Filings (Institutional Ownership Changes) for Novacyt (LON:NCYT)

Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Lab21 Products, IT-IS International, and Primerdesign segments. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The Primerdesign segment designs, manufactures, and markets molecular Â'real-time' qPCR testing devices and reagents in the areas of infectious diseases. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves public hospitals, central laboratories, private testing, and mobile laboratories. Novacyt S.A. was incorporated in 2006 and is headquartered in Camberley, the United Kingdom.
Read More on Novacyt

Today's Range

Now: GBX 248.20
Low: 247.80
High: 255.36

50 Day Range

MA: GBX 325.05
Low: 252.70
High: 426.30

52 Week Range

Now: GBX 248.20
Low: 245.60
High: 1,208.21

Volume

357,730 shs

Average Volume

719,609 shs

Market Capitalization

£175.29 million

P/E Ratio

2.07

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Novacyt?

Novacyt's top insider shareholders include:
  1. Andrew Heath (Insider)
  2. Edwin Snape (Insider)
  3. James Wakefield (Insider)
Investors- A $3T EV space could suffer without enough copper.
But this miner may sit on tons.
See why for yourself.